An Open-Label Multicenter Randomized Phase II Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination with Capecitabine or Capecitabine Monotherapy in Unresectable Locally Advanced or Metastatic Brea

This study is designed to compare how breast cancer responds to treatment with one of the three different treatements.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Breast Cancer
• Age: - 100 Years
• Gender: All